

George Simeon

Vice-President, Eli Lilly

George Simeon (99J) is a healthcare executive, entrepreneur, and board director with more than 30 years of global leadership experience across vaccines, biopharmaceuticals, medical devices, diagnostics, and healthcare technology. He has built and led healthcare organizations across North America, Europe, and Asia, with expertise in corporate strategy, capital formation, mergers and acquisitions, clinical development, market access, and corporate governance. He most recently served as Chief Executive Officer and Director of Curevo Vaccine, a clinicalstage biotechnology company developing next-generation vaccines. Under his leadership, Curevo raised more than \$200 million from leading healthcare investors, advanced its shingles vaccine candidate from IND through successful Phase 2 development to Phase 3 readiness, and completed a strategic transaction resulting in the company's \$1.5 billion acquisition by Eli Lilly. He also served as a Chairman of the Board and established an international Scientific and Regulatory Advisory Board comprising leading vaccine experts. George currently is NACD Certified in corporate governance. He holds an MBA from INSEAD, an MPH in Epidemiology and Health Economics from Yale University School of Medicine, and an MPhil from Bocconi University.